GGrantIndex
← Search

CORE--OLIGONUCLEOTIDE SYNTHESIS AND FERMENTOR

$167,178P30FY2002CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

Description: The Oligonucleotide Synthesis and Fermentor Shared Resource consists of two distinct components: an Oligonucleotide Synthesis Facility and a Fermentor Facility. The facility has been operational for over 10 years. The original facility, which had a single synthesizer, has now been expanded to include three different machines, capable of synthesizing a total of eight oligonucleotides at a time. Most of the support of this facility is derived from recharges to research grants. The current recharge rates are competitive with those of commercial companies for small scale synthesis of short oligonucleotides, and significantly cheaper for large scale synthesis of longer oligonucleotides and specially modified bases. In general, the application stated that it was possible to receive oligonucleotides on the same day of order, and in general the turn around time was one to two days for custom syntheses. Of note in the usage of the facility is that after a decline in usage in 1993-94 and 1994-95, usage increase in 1995-96. The facility will gel purify oligonucleotides at no additional charge upon request. Seventeen different investigators requested synthesis of oligonucleotides with modified bases. The fermentation facility maintains and operates two fermentors, one of 12 liter pilot scale and a second of 170 liter large scale capacity. The purpose of the facility is to offer large quantities of microbial cells for enzyme purifications and recombinant proteins for physical studies. The chargeback to investigators using the facility was significantly less than that cited for commercial sources. Usage of the facility included 26 charges to Center members, and 43 to non-members.

View original record on NIH RePORTER →